Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Johns Hopkins University |
---|---|
Information provided by: | Johns Hopkins University |
ClinicalTrials.gov Identifier: | NCT00390871 |
Dexmedetomidine (Precedex, Hospira) is a "super" selective alpha2-agonist - 8-10x more avid binding to alpha2 receptors than clonidine - and may have particularly favorable characteristics as a continuous i.v. infusion sedative for critically ill neuroscience patients. Its combination of anxiolysis, analgesia, without undue lethargy may make it an ideal agent where frequent neurological examinations are important (12). Unclear, however, is whether Precedex is superior to current common i.v. sedation protocols, and if there are any undue concerns of this agent on cerebral physiology and cortical stimulation.
Condition | Intervention | Phase |
---|---|---|
Sedation |
Drug: Precedex Drug: Propofol |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | Acute Neurological ICU Sedation Trial (ANIST) |
Enrollment: | 60 |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Study 1: Inclusion Criteria:
Neuroscience patients in the NCCU who are:
Study 1: Exclusion Criteria:
Study 2: Inclusion Criteria:
Critically ill neuroscience patients who are:
Study 2: Exclusion Criteria:
Study 3: Inclusion Criteria:
Critically ill neuroscience patients who are:
Study 3: Exclusion Criteria:
United States, Maryland | |
Johns Hopkins University | |
Baltimore, Maryland, United States, 21287 |
Principal Investigator: | Marek Mirski, MD, PhD | Johns Hopkins University |
Study ID Numbers: | ANIST |
Study First Received: | October 19, 2006 |
Last Updated: | March 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00390871 |
Health Authority: | United States: Institutional Review Board |
Patient Must be Under |
Dexmedetomidine Propofol |